Icecure Medical Ltd
TASE:ICCM
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IL |
I
|
Icecure Medical Ltd
TASE:ICCM
|
193.3m ILS |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
190.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.8B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
136.4B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
131.4B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
114.3B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.9B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.7B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.3B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
39.3B USD |
Loading...
|
Market Distribution
| Min | -85 210% |
| 30th Percentile | -8.6% |
| Median | 1.8% |
| 70th Percentile | 7.2% |
| Max | 23 652.1% |
Other Profitability Ratios
Icecure Medical Ltd
Glance View
IceCure Medical Ltd. is a commercial stage medical device company, which engages in the research and development, design, manufacture, and marketing of cryoablation systems and technologies based on liquid nitrogen for the treatment of tumors. The firm develops and markets minimally invasive cryoablation therapies for women’s health and general oncology market. Icecure Medical Ltd’s proprietary IceSense3 and ProSense systems provide minimally invasive, in-office definitive treatment for symptomatic tumors in various organs. The procedure is done under ultrasound or Computed Tomography (CT) imaging to guide a small probe (thin hollow needle) into the tumor. The system then uses extremely cold temperatures to destroy (ablate) the targeted tumor in situ. Icecure Medical Ltd supports investigator-initiated studies at various academic institutions around the globe, including Kameda and Saint Johns.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Icecure Medical Ltd is -534.7%, which is in line with its 3-year median of -534.7%.
Over the last 3 years, Icecure Medical Ltd’s Net Margin has decreased from -135.5% to -534.7%. During this period, it reached a low of -607% on Sep 30, 2022 and a high of -109.6% on Mar 31, 2021.
